To explore the impacts of blocking FAO‐ketogenesis processes on stroke severity, we applied the antagonist of CPT1α etomoxir (20 mg k−1g) to interrupt the rate‐limiting step of FAO and partially eliminate stroke‐induced BHB elevations (Figure S6A, Supporting Information). Here, CPT1A is linked to Stroke.